Table 1.
Genotype distribution for the six polymorphisms investigated in patients with CML and controls.
| Polymorphism | CML patients | Controls | OR (95% CI) | P value |
|---|---|---|---|---|
| n (%) | n (%) | CML versus controls | CML versus controls | |
| CAT C262T | ||||
| CC | 105 (62.5%) | 168 (52.3%) | — | — |
| CT | 49 (29.2%) | 132 (41.1%) | 0.59 (0.39–0.89) | 0.01 |
| TT | 14 (8.3%) | 21 (6.5%) | 1.06 (0.51–2.1) | 0.86 |
| GPX1 Pro198Leu | ||||
| Pro/Pro | 16 (9.5%) | 34 (10.6%) | — | — |
| Pro/Leu | 118 (70.2%) | 203 (63.2%) | 1.23 (0.65–2.3) | 0.51 |
| Leu/Leu | 34 (20.2%) | 84 (26.2%) | 0.86 (0.42–1.7) | 0.67 |
| MnSOD Ala16Val | ||||
| Ala/Ala | 1 (0.6%) | 1 (0.3%) | — | — |
| Ala/Val | 137 (81.5%) | 253 (78.8%) | 0.54 (0.03–8.7) | 0.95 |
| Val/Val | 30 (17.9%) | 67 (20.9%) | 0.44 (0.02–7.4) | 0.53 |
| GSTP1 | ||||
| Ile/Ile | 104 (61.9%) | 220 (68.5%) | — | — |
| Ile/Val | 51 (30.4%) | 90 (28%) | 1.2 (0.79–1.81) | 0.39 |
| Val/Val | 13 (7.7%) | 11 (3.5%) | 2.5 (1.08–5.7) | 0.02 |
| GSTM1 | ||||
| Present | 68 (40.5%) | 131 (40.8%) | — | — |
| Null | 100 (59.5) | 190 (59.2%) | 0.98 (0.67–1.4) | 0.94 |
| GSTT1 | ||||
| Present | 133 (79.2) | 67 (20.9%) | — | — |
| Null | 35 (20.8) | 254 (79.1%) | 0.91 (0.56–1.46) | 0.70 |
The bold font means statistically significant, P < 0.05.